Echinocandins are antifungal drugs built on a ring of six amino acids with a fatty side chain. They block the enzyme fungi use to build a key cell-wall sugar. This guide covers the four FDA-approved members: caspofungin, micafungin, anidulafungin and rezafungin. Sources were checked on November 17, 2026.
Quick answer: Echinocandins are prescription lipopeptide antifungals. Their labels cover Candida bloodstream and deep-tissue infections, and some cover esophageal candidiasis, aspergillosis or prevention of Candida infection. None of the four labels has a boxed warning. Liver effects and allergic reactions are shared warnings.
Vitrapep does not sell caspofungin, micafungin, anidulafungin or rezafungin; this page is a reference summary of published research and regulatory information.
What are echinocandins?
The National Library of Medicine defines echinocandins as “cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine” (MeSH, 2008). That six-amino-acid ring is why they count as peptides. Each member also carries a fat-like side chain, so the labels call them lipopeptides. Our peptide primer explains the basics.
All four start from a natural product made by a fungus, then are chemically modified. The Cancidas label says caspofungin is made “from a fermentation product of Glarea lozoyensis” (Cancidas label, 2022). Micafungin comes from a fermentation product of Coleophoma empetri. Anidulafungin and rezafungin both come from a fermentation product of Aspergillus nidulans. ChEBI text in PubChem calls anidulafungin “a heterodetic cyclic peptide” (PubChem CID 166548).
Drugs@FDA lists the original approvals as Cancidas (NDA 021227) on January 26, 2001, and Mycamine (NDA 021506) on March 16, 2005. Eraxis (NDA 021632) followed on February 17, 2006, and Rezzayo (NDA 217417) on March 22, 2023 (Drugs@FDA).
Echinocandins: key facts
| Fact | Caspofungin | Micafungin | Anidulafungin | Rezafungin |
|---|---|---|---|---|
| Structure type | Semisynthetic cyclic lipopeptide | Semisynthetic cyclic lipopeptide | Semisynthetic cyclic lipopeptide | Semisynthetic cyclic lipopeptide |
| Class | Echinocandin antifungal | Echinocandin antifungal | Echinocandin antifungal | Echinocandin antifungal |
| Molecular formula | C52H88N10O15 | C56H71N9O23S | C58H73N7O17 | C63H85N8O17+ (cation) |
| Molecular weight | 1,093.3 g/mol | 1,270.3 g/mol | 1,140.2 g/mol | 1,226.4 g/mol |
| First FDA approval | January 26, 2001 (NDA 021227) | March 16, 2005 (NDA 021506) | February 17, 2006 (NDA 021632) | March 22, 2023 (NDA 217417) |
| Brand names (US) | Cancidas (brand listed as discontinued) | Mycamine (brand listed as discontinued); generic labels | Eraxis | Rezzayo |
Formulas and weights are from PubChem (caspofungin, micafungin, anidulafungin, rezafungin).
How do echinocandins work?
Echinocandins attack the fungal cell wall, a structure human cells do not have. The Cancidas label says caspofungin “inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall” of susceptible Aspergillus and Candida species. The Rezzayo label says rezafungin “inhibits the 1,3-β-D-glucan synthase enzyme complex” (Rezzayo label, 2026).
Beta-glucan is a long sugar chain that gives the wall its strength. Without enough of it, the wall weakens. MeSH adds a chemistry note: the ring closes with one non-peptide bond, but echinocandins “lack ester links,” so they are not depsipeptides. Compare this with daptomycin, a bacterial lipopeptide that targets cell membranes instead.
What are echinocandins approved for?
Each label has its own list. In summary:
- Cancidas (caspofungin, 2001): presumed fungal infections in febrile, neutropenic patients; candidemia and Candida intra-abdominal abscesses, peritonitis and pleural space infections; esophageal candidiasis; and invasive aspergillosis in patients “refractory to or intolerant of other therapies.” Patients are adults and children 3 months and older.
- Micafungin (Mycamine, 2005): candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses; esophageal candidiasis; and “prophylaxis of Candida infections” in patients undergoing hematopoietic stem cell transplantation.
- Eraxis (anidulafungin, 2006): candidemia and Candida intra-abdominal abscess and peritonitis in patients 1 month and older; and esophageal candidiasis in adults.
- Rezzayo (rezafungin, 2023): candidemia and invasive candidiasis in adults and children 12 and older “who have limited or no alternative options.”
The labels share a limit: these drugs have not been studied, or adequately studied, in Candida endocarditis, osteomyelitis or meningitis. The Eraxis label also notes “high relapse rates in esophageal candidiasis” (Eraxis label, 2023).
What did the key trials show?
Caspofungin. A randomized, double-blind human trial enrolled 239 patients with invasive candidiasis. In the main analysis of 224 patients, success was 73.4% with caspofungin and 61.7% with amphotericin B. The difference was 12.7 percentage points (95.6% CI, −0.7 to 26.0) (Mora-Duarte et al., 2002).
Anidulafungin. A randomized, double-blind noninferiority trial compared anidulafungin with fluconazole in invasive candidiasis. Among 245 patients in the primary analysis, global response was 75.6% versus 60.2%. The difference was 15.4 percentage points (95% CI, 3.9 to 27.0) (Reboli et al., 2007).
Rezafungin. The phase 3 ReSTORE trial randomized 199 patients to rezafungin or caspofungin, double-blind (NCT03667690). The FDA primary end point was all-cause death by day 30. It occurred in 24% (22 of 93) with rezafungin and 21% (20 of 94) with caspofungin. The difference was 2.4% (95% CI, −9.7 to 14.4), meeting the noninferiority margin. Global cure at day 14 was 59% versus 61% (Thompson et al., 2023).
What side effects does the label list?
None of the four labels carries a boxed warning. Their most common adverse reactions:
- Cancidas (10% or more): diarrhea, fever, raised liver enzymes (ALT, AST and alkaline phosphatase) and low blood potassium.
- Micafungin: diarrhea, nausea, vomiting, abdominal pain, fever, low platelets, low neutrophils and headache.
- Eraxis (15% or more): low potassium, nausea, diarrhea, vomiting, fever, insomnia and low blood pressure.
- Rezzayo (151 patients): low potassium (15%), fever (12%), diarrhea (11%) and anemia (10%).
Warnings differ by label. Cancidas warns of allergic reactions, liver effects and raised liver enzymes when used with cyclosporine. Rezzayo warns of allergic reactions, photosensitivity and liver reactions. The micafungin label adds blood, liver and kidney effects (micafungin label, 2025).
Resistance matters for the fungi these drugs target. CDC estimated 34,800 drug-resistant Candida cases in hospitalized U.S. patients in 2017, with 1,700 deaths. CDC adds that “many are resistant to the antifungals used to treat them” (CDC, 2019).
What is the echinocandins’ regulatory status, and how are they used in research?
All four are prescription drugs in the United States. Drugs@FDA lists the Cancidas and Mycamine brand products as discontinued, while Eraxis and Rezzayo are listed as prescription products. DailyMed lists generic micafungin labels from makers such as Baxter, Fresenius Kabi and Sagent. The Rezzayo label is from Melinta Therapeutics.
The research summarized here is clinical: randomized human trials in invasive candidiasis. We found no documented role for echinocandins as laboratory reagents in the sources we checked.
Frequently asked questions about echinocandins
Are echinocandins peptides?
Yes. MeSH defines them as cyclic hexapeptides, a ring of six amino acids. A fatty side chain makes them lipopeptides.
When was the first echinocandin approved?
Drugs@FDA lists the original approval of Cancidas on January 26, 2001.
Which echinocandin is the newest?
Rezafungin. Drugs@FDA lists the original approval of Rezzayo on March 22, 2023.
Do echinocandins treat aspergillosis?
Among the four labels, only Cancidas lists invasive aspergillosis, and only in patients who did not respond to or could not tolerate other therapies.
Do echinocandins have a boxed warning?
No. Shared warnings include allergic reactions and liver effects.
What to know now
- Structure: semisynthetic cyclic hexapeptides with a fatty side chain (lipopeptides).
- Approval: Cancidas 2001, Mycamine 2005, Eraxis 2006, Rezzayo 2023; prescription only.
- Mechanism: block 1,3-beta-D-glucan synthase and weaken the fungal cell wall.
- Evidence: 73.4% vs 61.7% (caspofungin vs amphotericin B); 75.6% vs 60.2% (anidulafungin vs fluconazole).
- Label: Candida infections across all four; aspergillosis on Cancidas only.
- Safety: no boxed warnings; liver effects and allergic reactions are shared warnings.
What we’re watching
Further Rezzayo label revisions on DailyMed, last revised in July 2026. CDC updates on drug-resistant Candida. Related guides: daptomycin and dalbavancin, oritavancin and telavancin.